The Filing Desk

Tarsus Pharmaceuticals

TARS · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

TARS · Last close · November 13, 2026
$80.28
Value Tarsus Pharmaceuticals yourself

Tarsus Pharmaceuticals' revenue rose 146.7% to $451 million in fiscal 2025. Its operating margin was −15.7%, up from −65.9% a year earlier. Free cash flow was −$22 million. The diluted share count rose 11.1%.

TARSUS PHARMACEUTICALS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 23, 2026 · 0001819790-26-000019 Updated
Revenue
$451M
146.7%
Operating margin
−15.7%
50.2 pts
Net income
−$66M
 
Free cash flow
−$22M
 
Return on equity
−23.4%
31.4 pts
Market cap
$3.7B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Tarsus Pharmaceuticals does

Tarsus Pharmaceuticals is a biopharmaceutical company that sells an eye medicine and develops others. Its product, XDEMVY, is an eye drop approved by the FDA in July 2023 and launched in August 2023. It treats Demodex blepharitis, an infection of the eyelids by tiny mites that causes inflammation, redness and irritation. Left untreated, it can damage the cornea.

The company says the disease may affect as many as 25 million people in the United States. It earns its revenue from selling XDEMVY. The drug's active ingredient is lotilaner, which kills the mites. The company says XDEMVY has produced $646 million in net product sales since launch.

Tarsus is also studying lotilaner in other uses. TP-04 is a gel for ocular rosacea. TP-05 is a tablet being studied to prevent Lyme disease and to reduce malaria in communities. It has also tested XDEMVY in patients who have both Demodex blepharitis and meibomian gland disease, a blockage of the oil glands in the eyelid.

Its biggest risks, as it describes them

  • Depending heavily on sales of XDEMVY and on the success of its other product candidates.
  • The market for XDEMVY may turn out smaller than the company estimates.
  • Its product candidates may never win FDA approval or other regulatory approvals.
  • Side effects from its drugs could halt trials or hurt acceptance of XDEMVY.
  • Difficulty managing the growth of its sales, marketing and operations teams.
From Tarsus Pharmaceuticals's annual report on Form 10-K, filed February 23, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Tarsus Pharmaceuticals lost money in fiscal 2025: a net loss of $66 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments172217227291417
Debt incl. finance leases019307272
Net debt (negative means net cash)−172−198−198−220−345
Net debt to EBITDA—————
Debt to equity0.0x0.1x0.1x0.3x0.2x
Interest coverage—−28.5x−42.8x−15.4x−7.9x
Current ratio15.3x14.6x6.9x4.4x3.9x
Quick ratio15.3x14.6x6.8x4.4x3.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Tarsus Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Tarsus Pharmaceuticals shares on the open market, and 9 insiders sold $20.0 million, $12.7 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 15, 2026William J Phd LinkDirectorSold plan12,500$78.38$979,744Form 4
Sep 4, 2026Elizabeth Yeu LinChief Medical OfficerSold plan13,953$87.50$1.2 millionForm 4
Sep 4, 2026Bobak R. AzamianPresident/CEO and Board Chair, DirectorSold plan10,000$90.56$905,600Form 4
Sep 4, 2026Seshadri NeervannanChief Operating OfficerSold plan4,564$85.00$387,940Form 4
Sep 2, 2026Bobak R. AzamianPresident/CEO and Board Chair, DirectorSold plan10,000$80.06$800,600Form 4
Sep 2, 2026Elizabeth Yeu LinChief Medical OfficerSold plan6,977$80.00$558,160Form 4
Sep 1, 2026Elizabeth Yeu LinChief Medical OfficerSold plan4,601$73.86$339,830Form 4
Jun 17, 2026Bobak R. AzamianPresident/CEO and Board Chair, DirectorSold plan10,000$61.55$615,488Form 4
Jun 16, 2026Jeffrey S FarrowSee RemarksSold14,396$60.95$877,436Form 4
Jun 15, 2026William J Phd LinkDirectorSold plan12,500$62.12$776,495Form 4
Jun 15, 2026Katherine GoodrichDirectorSold plan2,954$62.08$183,384Form 4
Mar 20, 2026Seshadri NeervannanChief Operating OfficerSold plan2,989$66.75$199,516Form 4
The latest 12 of 40 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score1 of 83 of 84 of 8
Rule of 40−714.5%902.4%141.8%
Altman Z''1.811.092.84
Accruals ratio−7.5%−10.1%−11.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailPass
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score1 of 83 of 84 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Tarsus Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Tarsus PharmaceuticalsFY25146.7%−15.7%−4.9%——4
Arrowhead PharmaceuticalsFY26−45.6%−156.9%−63.0%——2Compare
ADMA BiologicsFY2519.6%37.5%5.5%39.5%−0.1x5Compare
Krystal BiotechFY2533.9%41.5%48.5%43.6%−5.0x5Compare
Twist BioscienceFY2520.3%−36.2%−20.1%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—0572617183451
Revenue growth———−54.7%−32.4%948.6%146.7%
Gross profit———————
Research and development3194243505364
Operating income−4−27−12−63−143−121−71
Net income−5−27−14−62−136−116−66
Diluted EPS (US$)−1.98−4.32−0.67−2.52−4.62−3.07−1.59
Diluted shares (millions)262125293842
Cash flow
Cash from operations−4−214−49−118−83−12
Capital expenditure00102210
Free cash flow−4−223−50−119−85−22
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation01814202842
Balance sheet at fiscal year end
Cash and short-term investments58168172217227291417
Debt incl. finance leases——019307272
Total assets58172179228266377562
Total liabilities16123568152219
Shareholders' equity−6166167193197224343
Margins and ratios
Gross margin———————
Operating margin——−21.3%−242.9%−820.5%−65.9%−15.7%
Net margin——−24.2%−240.5%−778.9%−63.2%−14.7%
Free cash flow margin——5.5%−191.9%−682.0%−46.2%−4.9%
Rule of 40 (growth + FCF margin)———−246.6%−714.5%902.4%141.8%
Return on capital———————
Return on equity—−33.5%−8.3%−34.5%−69.7%−54.8%−23.4%
Return on assets—−23.3%−7.9%−30.5%−55.1%−36.0%−14.1%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Tarsus Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Tarsus Pharmaceuticals.